About
Maculaser Ltd is a Finnish medical technology company dedicated to innovative treatments for retinal diseases, particularly age-related macular degeneration (AMD) and diabetic retinopathy. Founded in 2013, the company leverages research from Aalto University to develop patented laser therapy that uses temperature-controlled heat to stimulate natural healing in the retina. The company's technology offers a safe alternative to traditional treatments, providing real-time control of heat delivery to activate protective responses in retinal cells. This non-damaging approach aims to address early stages of retinal diseases, potentially reducing the need for more invasive late-phase treatments. Maculaser is advancing its clinical pipeline, preparing for trials focused on both wet and dry AMD, as well as macular edema. Maculaser collaborates with ophthalmologists and retinal specialists to bring its innovative therapy to market, aiming to enhance the quality of life for millions affected by retinal conditions. The company has secured funding to support its commercialization efforts and is part of the EU-funded PhotonMed initiative, which promotes advancements in retinal care.
Technologies
Keywords
Company Information
-
Employees 2
-
Founded 2020
-
Total Funding $1200000
Location
Helsinki, Uusimaa, Finland, 00290
